法莫替丁盐酸盐 | 125193-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 法莫替丁盐酸盐
• 中文别名: 法莫替丁单盐
• 英文名称: Famotidine hydrochloride
• 英文别名: 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide;hydrochloride
• CAS: 125193-62-6；108885-67-2
• 化学式: C₈H₁₅N₇O₂S₃*ClH
• 分子量: 373.912
• InChiKey: OONJNILIBCMSNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.35
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  238
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  famotidine 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 法莫替丁盐酸盐
  参考文献：
  名称：

  A process for the preparation of a combination of famotidine polymorphs A and B

  摘要：

  揭示了一种制备法莫替丁（化学名称为N-磺胺基-3-(2-胍基噻唑-4-基甲硫基)丙酰胺）多形态A和B的组合物的方法。

  公开号：

  EP1361221A1

文献信息

• New-quanidino-thiazol compounds, their preparation, and use as intermediates of famotidine process
  申请人：CENTRO MARGA PARA LA INVESTIGACION S.A.

  公开号：EP0322335A1

  公开（公告）日：1989-06-28

  New 2-guanidino-thiazol compounds with the general formulas where R° represents an hydrogen atom or an alkyl group of low molecular weight, m = 2 to 7, n = 2 to 4, and being R an alkyl group of low molecular weight and that may contain from one N-alkylsilyl group, that are important intermediates for the famotidine preparation, medically used as inhibitor of the gastric secretion.

  具有一般公式的新2-胍基噻唑化合物，其中R°代表氢原子或低分子量的烷基基团，m = 2至7，n = 2至4，R是低分子量的烷基基团，可能含有一个N-烷基硅基团，这些化合物是法莫替定制备的重要中间体，医学上用作胃分泌抑制剂。
• PREPARATIONS FOR MEASRUING GASTRIC pH VALUE AND METHOD OF MEASURING GASTRIC pH VALUE BY USING THE SAME
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1312381A1

  公开（公告）日：2003-05-21

  The present invention provides a preparation for easily and non-invasively measuring gastric pH, for example, a preparation for measuring gastric pH using the expired air, and a method for measuring gastric pH using the preparation. The preparation of the present invention can be produced by covering a composition containing a compound labeled with an isotope (13C, 14C, 15N, or 18O), with a pH-dependent soluble base.

  本发明提供了一种易于无创测量胃 pH 值的制剂，例如利用呼出空气测量胃 pH 值的制剂，以及利用该制剂测量胃 pH 值的方法。本发明的制剂可以通过将含有用同位素（13C、14C、15N 或 18O）标记的化合物的组合物与依赖于 pH 值的可溶性碱覆盖在一起而制成。
• Gastric acid secretion inhbiting compositon
  申请人：Orexo AB

  公开号：EP1731141A2

  公开（公告）日：2006-12-13

  An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration and to keep it at that level for at least 4 hours. Also disclosed is a method of manufacture of the dosage form, its use in treating dyspepsia and infection by Helicobacter pylori, and a method of treating disorders associated with gastric acid secretion.

  一种口服药物剂型包含药理有效量的易酸质子泵抑制剂或其盐、H2 受体拮抗剂或其盐以及药学上可接受的载体。该剂型能够在给药后两小时内将胃液 pH 值提高到 4 以上，并在至少 4 小时内保持该水平。此外，还公开了该剂型的制造方法、其在治疗消化不良和幽门螺旋杆菌感染中的用途，以及治疗与胃酸分泌有关的疾病的方法。
• Gastric acid secretion inhibiting composition
  申请人：Orexo AB

  公开号：EP2253309A2

  公开（公告）日：2010-11-24

  An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration and to keep it at that level for at least 4 hours. Also disclosed is a method of manufacture of the dosage form, its use in treating dyspepsia and infection by Helicobacter pylori, and a method of treating disorders associated with gastric acid secretion.

  一种口服药物剂型包含药理有效量的易酸质子泵抑制剂或其盐、H2 受体拮抗剂或其盐以及药学上可接受的载体。该剂型能够在给药后两小时内将胃液 pH 值提高到 4 以上，并在至少 4 小时内保持该水平。此外，还公开了该剂型的制造方法、其在治疗消化不良和幽门螺旋杆菌感染中的用途，以及治疗与胃酸分泌有关的疾病的方法。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。